Important to the development of any treatment for scleroderma is a clinical study investigating the pharmacodynamics and pharmacokinetics of a potential drug candidate. NexMed (USA), Inc., a subsidiary of Apricus Biosciences, Inc., is sponsoring a currently enrolling clinical trial investigating these two aspects of alprostadil in systemic sclerosis (SSc)…
News
A Phase 1 clinical trial recently ended that involved “A Study of the Safety and Tolerability of MEDI-551 in Scleroderma.” MedImmune LLC, sponsor of the study, last updated the results of the trial in an abstract presented through Annals of the…
As patients with scleroderma and Raynaud’s phenomenon know, cold hands can be extremely bothersome and even painful. Fredrick M. Wigley, MD, of Johns Hopkins University led a phase 3 clinical trial in 2014 that evaluated Fasudil, a Rho-kinase inhibitor, for efficacy in preventing vasoconstriction in the fingers and skin,…
“Zibotentan Better Renal Scleroderma Outcome Study (ZEBRA)” is more than a standard clinical trial for scleroderma patients. Rather, the phase 2 clinical trial is a three-part clinical trial seeking to help patients with mild, moderate, or severe kidney disease due to scleroderma. University College, London is…
“Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma,” a clinical trial currently recruiting patients, is looking to add another possible remedy to the list for systemic sclerosis (SSc). In the trial, fractional carbon dioxide laser treatment will be compared against UVA1…
An ongoing clinical trial is evaluating RoActemra/Actemra (tocilizumab) in patients with systemic sclerosis (SSc). Sponsored by Hoffmann-La Roche, this clinical trial is in phase 3, with primary outcomes of a change in modified Rodnan skin score (mRSS) and incidence of adverse events. Currently…
Certain patients with systemic sclerosis (SSc) may be at a higher risk for malignancies based on autoantibodies present in their blood. Specifically, work presented by Dr. Cosimo Bruni at the 2014 American College of Rheumatology Annual Meeting, “An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy…
San Diego-based regenerative medicine company Cytori Therapeutics, Inc. has just announced it will be hosting an information session on scleroderma, and a presentation of its key STAR clinical trial. Lead investigator on the STAR trial, Dr. Dinesh Khanna, will be conducting the discussion on January 14,…
Scientists from the Department of Dermatology at the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan have confirmed that antibodies to a specific enzyme — RNA polymerase III — are associated with scleroderma renal crisis (SRC). RNA polymerase III’s normal function is to convert (transcribe) DNA into RNA. Antibodies to RNA polymerase III are called anti-RNAP…
Biopharmaceutical company Apricus Biosciences, Inc. has announced that it has enrolled the first patient its phase 2a clinical trial for the assessment of the company’s main candidate for treating Raynaud’s phenomenon secondary to scleroderma. The investigational drug, which is comprised of an on-demand topical cream for the afflicted extremities, is…
Recent Posts
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show
- Milk-derived particles may offer treatment path for SSc fibrosis